Cereulide
Based on 1 Customer Validation
Cereulide is an orally active, blood-brain barrier-permeable emetic toxin. Cereulide acts as a potassium ionophore that inserts into membranes, forms complexes with K+, and transports K+ from the cytoplasm into the mitochondrial matrix. Cereulide disrupts the electrochemical gradient of the inner mitochondrial membrane, leading to mitochondrial swelling and dysfunction, uncoupling of oxidative phosphorylation, inhibition of ATP synthesis, ROS accumulation, and ultimately triggering apoptosis and autophagy. Cereulide exhibits multi-organ toxicity and can be used for research on emetic food poisoning.
For research use only. We do not sell to patients.
- Purity : 95.05%
- CAS No.: 157232-64-9
- Formula: C57H96N6O18
- Molecular Weight:1153.40
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
In Vitro
Cereulide (<1 ng/mL, chronic; 0.05-0.5 nM, 10 days; 0.2-500 nM, 24 h) induces mitochondrial dysfunction, impairs intestinal barrier function, inhibits cell proliferation, and triggers inflammation in Caco-2 cells, with maximal respiration reduced to 2% of baseline and ATP production to 6% of baseline at 0.5 nM after 10 days of exposure[1].
Cereulide (0.05-0.5 ng/mL, 24 h; 1 ng/mL, 2 days; 10 ng/mL, 8-24 h) dose-dependently impairs glucose-stimulated insulin secretion and induces apoptosis and necrosis in MIN6 cells and pancreatic islets, with complete loss of insulin secretion at 0.25 ng/mL in MIN6 cells after 24 h of exposure[1].
Cereulide (0.05-0.5 nM, 10 days) induces severe mitochondrial dysfunction in HepG2 cells, with maximal respiration reduced to 2% of baseline and ATP production to 6% of baseline at 0.5 nM after 10 days of exposure[1].
Cereulide (20 ng/mL, 1 min; 100-1000 ng/mL, 3 h; unspecified, 1 day) rapidly impairs cytotoxic function, induces mitochondrial damage, and triggers apoptosis in NK cells, with loss of cytotoxic capacity observed within 1 min of exposure to 20 ng/mL[1].
Cereulide (2.74-2.98 ng/mL; 24 h) reduces viability of HepaRG cells with an IC50 of 2.98 ng/mL and HEK293T cells with an IC50 of 2.74 ng/mL after 24 h of treatment[2].
Cereulide (0.3-1 ng/mL; 24 h) induces dose-dependent apoptosis in HepaRG and HEK293T cells after 24 h of treatment with 0.3 or 1 ng/mL[2].
Cereulide (0.3-1 ng/mL; 24 h) induces structural damage including mitochondrial dysfunction and apoptotic morphological changes in HepaRG and HEK293T cells after 24 h of treatment with 0.3 or 1 ng/mL[2].
Cereulide (0.3-1 ng/mL; 24 h) induces ER swelling in HepaRG and HEK293T cells after 24 h of treatment with 0.3 or 1 ng/mL[2].
Cereulide (0.3-1 ng/mL; 3-24 h) activates the IRE1α/XBP1 and PERK/eIF2α ER stress pathways and upregulates pro-apoptotic CHOP in a time- and dose-dependent manner in HepaRG and HEK293T cells after treatment with 0.3 or 1 ng/mL for 3, 6, or 24 h[2].
Cereulide (0.3-1 ng/mL; 24 h) induces dose-dependent ROS accumulation in HepaRG and HEK293T cells after 24 h of treatment with 0.3 or 1 ng/mL[2].
Cereulide (0.5-1 ng/mL; 4 h) induces ER stress (increased p-eIF2α and CHOP) in HepaRG and HEK293T cells treated with 1 ng/mL or 0.5 ng/mL for 4 h that is mediated by ROS accumulation[2].
Cereulide (1 ng/mL; 48 h) reduces insulin content and increases cell death in fetal porcine islets of Langerhans[3].
Cereulide (10 ng/mL; 8-24 h) induces loss of mitochondrial membrane potential and necrotic/pyknotic cell death in murine insulinoma MIN6 cells[3].
Cereulide (5 ng/mL; 24 h) induces high rates of apoptosis in rat INS-1E cells, murine insulinoma MIN6 cells, and freshly isolated murine pancreatic islets[3].
Cereulide (0.5 ng/mL; 24 h) impairs mitochondrial structure and function, increases reactive oxygen species, and induces apoptosis in murine insulinoma MIN6 cells[3].
Cereulide (0.15-0.5 ng/mL; 24 h) significantly reduces or completely inhibits glucose-stimulated insulin secretion in murine insulinoma MIN6 cells and freshly isolated murine pancreatic islets[3].
Cereulide (2 nM) inhibits RNA synthesis in human hepatocellular carcinoma HepG2 cells[3].
Cereulide (0.1-50 ng/mL; 5 h, 24 h) reduces cell viability of HepG2 liver cells in a concentration- and time-dependent manner, with cytotoxicity observed at lower concentrations after 24 h compared to 5 h[4].
Cereulide (0.1-50 ng/mL; 5 h, 24 h) alters mitochondrial quantity and morphology in HepG2 liver cells, with an initial increase in mitochondrial number at 0.1 ng/mL followed by concentration-dependent decreases at higher concentrations, and mitochondrial aberrations detected at 2.5 ng/mL after 24 h[4].
Cereulide (0.1-50 ng/mL; 5 h, 24 h) increases lysosomal number and/or size in HepG2 liver cells at concentrations 0.1-5 ng/mL after 5 and 24 h, with a maximum increase to 136% of solvent control at 2.5 ng/mL after 24 h, while higher concentrations reduce lysosomal signal[4].
Cereulide (0.1-50 ng/mL; 5 h, 24 h) increases lysosomal acidification in HepG2 liver cells at concentrations 2.5-50 ng/mL after 24 h, with no significant effects detected after 5 h[4].
Cereulide (0.1-1 ng/mL; 5 h, 24 h) upregulates transcription of autophagy-related genes MAP1LC3B and SQSTM1 in HepG2 liver cells at 1 ng/mL after 5 and 24 h, while marginally reducing transcription of lysosomal and other autophagy-related genes[4].
Cereulide (0.1-1 ng/mL; 24 h) increases LC3 protein expression in HepG2 liver cells at 0.1 and 1 ng/mL after 24 h, indicating induction of autophagy via the LC3 pathway[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepaRG cells, HEK293T cells
-
Concentration:0.3 and 1 ng/mL
-
Incubation Time:24 h
-
Result:Caused a dose-dependent significant increase in the number of apoptotic cells in both HepaRG and HEK293T cells.
-
Cell Line:HepaRG cells, HEK293T cells
-
Concentration:0.3 and 1 ng/mL
-
Incubation Time:3, 6 and 24 h
-
Result:Caused time- and dose-dependent increases in phosphorylation of IRE1α and PERK, phosphorylation of eIF2α, levels of XBP1(s), and levels of CHOP in both cell lines.
Did not increase BiP levels at 3 h or 6 h, but significantly increased BiP levels at 24 h.
-
Cell Line:HepaRG cells, HEK293T cells
-
Concentration:0.5 ng/mL (HEK293T cells); 1 ng/mL (HepaRG cells)
-
Incubation Time:4 h
-
Result:Induced increases in p-eIF2α and CHOP levels that were reversed by NAC pretreatment in both cell lines.
-
Cell Line:Murine insulinoma MIN6 cells
-
Concentration:0.5 ng/mL
-
Incubation Time:24 h
-
Result:Caused swollen, disintegrated mitochondria in murine insulinoma MIN6 cells.
Increased reactive oxygen species by more than twofold in murine insulinoma MIN6 cells.
Reduced basal respiration rate to half in murine insulinoma MIN6 cells.
Increased caspase 3/7 activation in murine insulinoma MIN6 cells.
Elevated cytochrome C release into the cytoplasm in murine insulinoma MIN6 cells.
Upregulated pro-apoptotic mRNA markers including CHOP in murine insulinoma MIN6 cells.
-
Cell Line:HepG2 liver cells
-
Concentration:0.1, 1, 2.5, 5, 10 and 50 ng/mL
-
Incubation Time:5 h; 24 h
-
Result:Reduced cell viability to approximately 65-70% starting from 2.5 ng/mL after 5 h incubation.
Reduced cell viability to 46% at the highest tested concentration after 24 h incubation.
-
Cell Line:HepG2 liver cells
-
Concentration:0.1, 1, 2.5, 5, 10 and 50 ng/mL
-
Incubation Time:5 h; 24 h
-
Result:Increased MAP1LC3B and SQSTM1 transcript levels at 1 ng/mL after 5 h incubation.
Marginally reduced LAMP2, CTSD, and ATG16 transcript levels at 0.1 and 1 ng/mL after 5 h incubation.
Increased MAP1LC3B transcript levels to ~2.7-fold of solvent control at 1 ng/mL after 24 h incubation.
Increased SQSTM1 transcript levels to ~2.5-fold of solvent control at 1 ng/mL after 24 h incubation.
Reduced CTSD transcript levels to below 0.5-fold of solvent control at 1 ng/mL after 24 h incubation.
Marginally reduced LAMP2 and ATG16 transcript levels at 0.1 and 1 ng/mL after 24 h incubation.
-
Cell Line:HepG2 liver cells
-
Concentration:0.1 and 1 ng/mL
-
Incubation Time:24 h
-
Result:Increased LC3 fluorescence intensity to ~130% of solvent control at 0.1 ng/mL after 24 h incubation.
Increased LC3 fluorescence intensity to ~150% of solvent control at 1 ng/mL after 24 h incubation, similar to the positive control rapamycin.
In Vivo
Cereulide (10-20 μg per mouse; i.p.; single administration) induces dose-dependent hepatotoxicity in male BALB/c mice, with 20 μg being a lethal dose, 10 μg causing reversible toxicity, and 15 μg leading to significant liver injury[3].
Cereulide-containing *Bacillus cereus* cultures induce microvesicular steatosis and midzonal necrosis in rat livers, replicating fatal human hepatotoxicity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (6-week-old, male, SPF, acclimated for 1 week post-purchase)[2]
-
Dosage:10 μg/kg; 50 μg/kg; 200 μg/kg
-
Administration:p.o.; daily; 28 days
-
Result:Significantly decreased body weight; increased kidney and spleen indices; induced hepatocyte and glomerular swelling, inflammatory cell infiltration; increased mRNA levels of IL-6 and TNF-α in liver and kidney; significantly decreased SOD activity in liver and kidney; significantly increased MDA level in liver; increased mRNA levels of XBP1(s) and ATF4, and increased protein/phosphorylation levels of IRE1α/XBP1(s) and PERK/eIF2α/CHOP in liver and kidney; reached ~20% TUNEL-positive apoptotic cells in liver and ~22% in kidney (50 μg/kg).
-
Animal Model:BALB/c (male)[3]
-
Dosage:20 μg; 15 μg; 10 μg
-
Administration:i.p.; single dose
-
Result:Caused lethality at 20 μg
Induced marked hepatocyte swelling (due to mitochondrial swelling) and elevation of serum transaminases at 15 μg.
Allowed full recovery 4 weeks after 10 μg.
Chemical Information
-
CAS No. 157232-64-9
-
Appearance Solid
-
Molecular Weight 1153.40
-
Formula C57H96N6O18
-
Color White to off-white
-
Structure Classification
-
Initial Source
Bacillus cereus
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (86.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
-
Data Sheet (312 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1].
Yang S, et al. Cereulide and Emetic Bacillus cereus: Characterizations, Impacts and Public Precautions. Foods. 2023 Feb 15;12(4):833.
[Content Brief]
[2]. Li D, et al. Cereulide Exposure Caused Cytopathogenic Damages of Liver and Kidney in Mice. Int J Mol Sci. 2021;22(17):9148. Published 2021 Aug 24. [Content Brief]
[3]. Vangoitsenhoven R, et al. Cereulide food toxin, beta cell function and diabetes: Facts and hypotheses. Diabetes Res Clin Pract. 2015;109(1):1-5. [Content Brief]
[4]. Beisl J, et al. Cereulide and Deoxynivalenol Increase LC3 Protein Levels in HepG2 Liver Cells. Toxins (Basel). 2022;14(2):151. Published 2022 Feb 18. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8670 mL | 4.3350 mL | 8.6700 mL | 21.6750 mL |
| 5 mM | 0.1734 mL | 0.8670 mL | 1.7340 mL | 4.3350 mL | |
| 10 mM | 0.0867 mL | 0.4335 mL | 0.8670 mL | 2.1675 mL | |
| 15 mM | 0.0578 mL | 0.2890 mL | 0.5780 mL | 1.4450 mL | |
| 20 mM | 0.0434 mL | 0.2168 mL | 0.4335 mL | 1.0838 mL | |
| 25 mM | 0.0347 mL | 0.1734 mL | 0.3468 mL | 0.8670 mL | |
| 30 mM | 0.0289 mL | 0.1445 mL | 0.2890 mL | 0.7225 mL | |
| 40 mM | 0.0217 mL | 0.1084 mL | 0.2168 mL | 0.5419 mL | |
| 50 mM | 0.0173 mL | 0.0867 mL | 0.1734 mL | 0.4335 mL | |
| 60 mM | 0.0145 mL | 0.0723 mL | 0.1445 mL | 0.3613 mL | |
| 80 mM | 0.0108 mL | 0.0542 mL | 0.1084 mL | 0.2709 mL |